Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Tania Jain; Merav Bar; Ankit J Kansagra; Elise A Chong; Shahrukh K Hashmi; Sattva S Neelapu; Michael Byrne; Elad Jacoby; Aleksandr Lazaryan; Caron A Jacobson; Stephen M Ansell; Farrukh T Awan; Linda Burns; Veronika Bachanova; Catherine M Bollard; Paul A Carpenter; John F DiPersio; Mehdi Hamadani; Helen E Heslop; Joshua A Hill; Krishna V Komanduri; Craig A Kovitz; Hillard M Lazarus; Justin M Serrette; Mohamad Mohty; David Miklos; Arnon Nagler; Steven Z Pavletic; Bipin N Savani; Stephen J Schuster; Mohamed A Kharfan-Dabaja; Miguel-Angel Perales; Yi Lin

doi:10.1016/j.bbmt.2019.08.015

$Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy$

Journal article

Peer reviewed

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Tania Jain, Merav Bar, Ankit J Kansagra, Elise A Chong, Shahrukh K Hashmi, Sattva S Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A Jacobson, …

Biology of blood and marrow transplantation, Vol.25(12), pp.2305-2321

2019-12

DOI: https://doi.org/10.1016/j.bbmt.2019.08.015

PMID: 31446199

Abstract

Non-Hodgkin lymphoma

Chimeric antigen receptor T cell therapy

Diffuse large B cell lymphoma

Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.

Metrics

13 Record Views

108 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.6 Immunology; 1.6.214 PD-1
Web Of Science research areas: Hematology; Immunology; Transplantation
ESI research areas: Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
Creators: Tania Jain - Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Merav Bar - Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington
Ankit J Kansagra - Department of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Elise A Chong - Lymphoma Program, Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Shahrukh K Hashmi - Division of Hematology, Mayo Clinic, Rochester, Minnesota
Sattva S Neelapu - Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas
Michael Byrne - Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Elad Jacoby - The Chaim Sheba Medical Center, Tel-Hashomer, Affiliated with the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Aleksandr Lazaryan - Blood and Marrow Transplant and Cellular Immunotherapy Program, Moffitt Cancer Center, Tampa, Florida
Caron A Jacobson - Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, Massachusetts
Stephen M Ansell - Division of Hematology, Mayo Clinic, Rochester, Minnesota
Farrukh T Awan - Department of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
Linda Burns - National Marrow Donor Program and Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota
Veronika Bachanova - Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota
Catherine M Bollard - Center for Cancer and Immunology Research, Children's National Health System, Washington, DC
Paul A Carpenter - Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington
John F DiPersio - Division of Oncology, Washington University School of Medicine, St Louis, Missouri
Mehdi Hamadani - Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
Helen E Heslop - Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas
Joshua A Hill - Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington
Krishna V Komanduri - Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, Florida
Craig A Kovitz - Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Hillard M Lazarus - Division of Hematology and Oncology, Case Western Reserve University, Cleveland, Ohio
Justin M Serrette - Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas
Mohamad Mohty - Hematology and Cellular Therapy Department, Saint-Antoine Hospital, AP-HP, Sorbonne University, INSERM UMRs 938, Paris, France
David Miklos - Division of Blood and Marrow Transplantation, Stanford University, Stanford, California
Arnon Nagler - Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Steven Z Pavletic - Graft-versus-Host and Late Effects Section, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland
Bipin N Savani - Division of Hematology and Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
Stephen J Schuster - Lymphoma Program, Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania
Mohamed A Kharfan-Dabaja - Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida
Miguel-Angel Perales - Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Yi Lin - Division of Hematology, Mayo Clinic, Rochester, Minnesota
Publication Details: Biology of blood and marrow transplantation, Vol.25(12), pp.2305-2321
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 31446199
Record Identifier: 991031599214502976